This compound is primarily used in the field of oncology as a PI3K inhibitor, targeting the PI3K pathway which is often dysregulated in various cancers. It is investigated for its potential to inhibit tumor growth and proliferation in cancers such as breast cancer, glioblastoma, and other solid tumors. In clinical trials, it has been explored both as a monotherapy and in combination with other anticancer agents to enhance efficacy. Additionally, it is studied for its role in overcoming resistance to other treatments, particularly in hormone receptor-positive breast cancer. Its application extends to research settings where it is used to understand the molecular mechanisms of PI3K signaling in cancer biology.